Mochida Pharma Anti-Depression Drug MHD-55 Enters Phase III Trial
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Mochida Pharma announced that anti-depression drug MHD-55 (escitalopram) has entered Phase III trials. The company's pulmonary arterial hypertension drug MD-0701 (treprostinil), and a cell drug jointly developed with Japan Chemical Research Pharma will enter clinic trials this year. Mochida also plans to start Beselna Cream (imiquimod) clinic trials for additional applications of treating solar kerasotes. Currently imiquimod is a therapeutic agent for condyloma acuminatum. As part of its growth strategy, Mochida has been actively seeking and in-licensing products that have been marketed overseas to add to the company's product lineup. (Click here for more - Japanese language)